A phase I, open label study to assess the safety and tolerability of ZD6474 (Zactima) [vandetanib] in combination with vinorelbine (Navelbine) or gemcitabine (Gemzar) plus cisplatin as first line therapy in patients with locally advanced or metastatic (stage IIIB-IV) non small cell lung cancer.

Trial Profile

A phase I, open label study to assess the safety and tolerability of ZD6474 (Zactima) [vandetanib] in combination with vinorelbine (Navelbine) or gemcitabine (Gemzar) plus cisplatin as first line therapy in patients with locally advanced or metastatic (stage IIIB-IV) non small cell lung cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Cisplatin; Gemcitabine; Vandetanib; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 17 Dec 2007 Status change from in progress to completed.
    • 04 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top